Cite
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial.
MLA
Shiota, Masaki, et al. “Effect of Genetic Polymorphisms on Outcomes Following Nivolumab for Advanced Renal Cell Carcinoma in the SNiP-RCC Trial.” Cancer Immunology, Immunotherapy, vol. 72, no. 6, June 2023, pp. 1903–15. EBSCOhost, https://doi.org/10.1007/s00262-023-03367-w.
APA
Shiota, M., Miyake, H., Takahashi, M., Oya, M., Tsuchiya, N., Masumori, N., Matsuyama, H., Obara, W., Shinohara, N., Fujimoto, K., Nozawa, M., Ohba, K., Ohyama, C., Hashine, K., Akamatsu, S., Kamba, T., Mita, K., Gotoh, M., Tatarano, S., & Fujisawa, M. (2023). Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial. Cancer Immunology, Immunotherapy, 72(6), 1903–1915. https://doi.org/10.1007/s00262-023-03367-w
Chicago
Shiota, Masaki, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya, Naoya Masumori, Hideyasu Matsuyama, et al. 2023. “Effect of Genetic Polymorphisms on Outcomes Following Nivolumab for Advanced Renal Cell Carcinoma in the SNiP-RCC Trial.” Cancer Immunology, Immunotherapy 72 (6): 1903–15. doi:10.1007/s00262-023-03367-w.